Reversibility of blue-gray cutaneous discoloration from amiodarone.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 2072759.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 45-year-old man had severe blue-gray cutaneous discoloration during amiodarone therapy for atrial fibrillation. Therefore, this drug regimen was discontinued, and long-term anticoagulation and digoxin therapy were used. The patient was advised to avoid exposure of his skin to sunlight, and a bleaching agent was prescribed. After 18 months of follow-up, the blue-gray hyperpigmentation had diminished. Although photosensitivity reactions from amiodarone occur in more than 50% of patients, blue-gray cutaneous discoloration occurs in less than 10% of patients on prolonged therapy with amiodarone. The presence of high concentrations of iodine, detected by electron probe analysis, suggests that the cutaneous deposits are amiodarone itself or a metabolite. The slow rate of elimination of amiodarone and a high uptake by fat-associated tissues may explain the delayed disappearance of cutaneous photosensitivity and late resolution of the blue-gray discoloration. Our current case supports the reversibility of these adverse effects on long-term follow-up.
Medical subject headings
- Amiodarone
- Amiodarone/adverse effects
- Amiodarone/therapeutic use
- Atrial Fibrillation
- Atrial Fibrillation/drug therapy
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Photosensitivity Disorders
- Photosensitivity Disorders/chemically induced
- Photosensitivity Disorders/complications
- Pigmentation Disorders
- Pigmentation Disorders/chemically induced
- Pigmentation Disorders/complications
- Pigmentation Disorders/pathology